Cencora Inc.
Cencora Reports Q2 2025 Results and Raises Adjusted EPS Guidance
Summary
Cencora, Inc. reported a 10.3% increase in revenue for the second quarter of fiscal 2025, reaching $75.5 billion. The company announced GAAP diluted EPS of $3.68 and adjusted diluted EPS of $4.42, a 16.3% increase from the prior year. Cencora raised its adjusted diluted EPS guidance for fiscal 2025 to a range of $15.70 to $15.95. Additionally, the company declared a quarterly cash dividend of $0.55 per common share, payable on June 2, 2025. A conference call was scheduled for May 7, 2025, to discuss these results.
Profitelligence Alerts
Get alerts for COR
Be first to know when Cencora Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cencora Inc.
Cencora Inc., formerly known as AmerisourceBergen Corporation, represents a pivotal entity in the global healthcare distribution and services sector. As a leading pharmaceutical sourcing and distribution services company, Cencora Inc. plays a critical role in ensuring the efficient supply of pharmaceutical products to a range of healthcare providers, including hospitals, pharmacies, and clinics. Its business model is centered on the seamless integration of logistics, consulting services, and the provision of innovative solutions aimed at improving pharmaceutical supply chain operations. Cencora Inc. impacts various segments of the healthcare industry by enhancing the availability and accessibility of healthcare products. Known for its global reach and extensive network of distribution centers, the company supports the delivery of critical medications and healthcare products across numerous geographies. Cencora Inc.'s significance in the market is underscored by its ability to partner with pharmaceutical manufacturers and healthcare providers to streamline processes, reduce costs, and improve patient outcomes. Headquartered in Conshohocken, Pennsylvania, Cencora Inc. remains a cornerstone of the healthcare distribution market, focusing on sustainability, innovation, and strategic collaborations.
Official SEC Documents
Advertisement